1. Sources of inter-individual variability leading to significant changes in anti-PD-1 and anti-PD-L1 efficacy identified in mouse tumor models using a QSP framework
    Jessica C. Leete et al, 2022, Frontiers in Pharmacology CrossRef
  2. Peripheral Blood Transcriptome in Breast Cancer Patients as a Source of Less Invasive Immune Biomarkers for Personalized Medicine, and Implications for Triple Negative Breast Cancer
    Helena Čelešnik et al, 2022, Cancers CrossRef
  3. PD-L1, a Potential Immunomodulator Linking Immunology and Orthodontically Induced Inflammatory Root Resorption (OIIRR): Friend or Foe?
    Jiawen Yong et al, 2022, International Journal of Molecular Sciences CrossRef
  4. Programmed Cell Death Protein 1 (PD-1) in Relation to PANoptosis: Immune Pharmacological Targets for Management of Breast Adenocarcinoma
    Subarnarekha Maitra et al, 2023, Endocrine, Metabolic & Immune Disorders - Drug Targets CrossRef
  5. Case Report: Squamous Cell Carcinoma of Pancreas With High PD-L1 Expression: A Rare Presentation
    Baohong Yang et al, 2021, Frontiers in Oncology CrossRef
  6. Nature vs. Nurture: The Two Opposing Behaviors of Cytotoxic T Lymphocytes in the Tumor Microenvironment
    Nagaja Capitani et al, 2021, International Journal of Molecular Sciences CrossRef
  7. Research Progress of DCLK1 Inhibitors as Cancer Therapeutics
    Linna Cheng et al, 2022, Current Medicinal Chemistry CrossRef
  8. NLRP3 as Putative Marker of Ipilimumab-Induced Cardiotoxicity in the Presence of Hyperglycemia in Estrogen-Responsive and Triple-Negative Breast Cancer Cells
    Vincenzo Quagliariello et al, 2020, International Journal of Molecular Sciences CrossRef
  9. Knockdown of Leptin Receptor Affects Macrophage Phenotype in the Tumor Microenvironment Inhibiting Breast Cancer Growth and Progression
    Luca Gelsomino et al, 2020, Cancers CrossRef
  10. Natural Killer Cell Engagers (NKCEs): a new frontier in cancer immunotherapy
    Minchuan Zhang et al, 2023, Frontiers in Immunology CrossRef
  11. Immunotherapy Study on Non-small-Cell Lung Cancer (NSCLC) Combined with Cytotoxic T Cells and miRNA34a
    Richa Pandey et al, 2024, Molecular Pharmaceutics CrossRef
  12. Boron Derivatives Inhibit the Proliferation of Breast Cancer Cells and Affect Tumor-Specific T Cell Activity In Vitro by Distinct Mechanisms
    Eslam Essam Mohammed et al, 2023, Biological Trace Element Research CrossRef
  13. Chemokines in progression, chemoresistance, diagnosis, and prognosis of colorectal cancer
    Qian Zou et al, 2022, Frontiers in Immunology CrossRef
  14. The expression of FLNA and CLU in PBMCs as a novel screening marker for hepatocellular carcinoma
    Rathasapa Patarat et al, 2021, Scientific Reports CrossRef
  15. Synthesis and Preliminary Evaluations of [18F]fluorinated Pyridine-2- carboxamide Derivatives for Targeting PD-L1 in Cancer
    Samuel Samnick et al, 2023, Current Cancer Drug Targets CrossRef
  16. PD-L1 Expression Is Associated with Deficient Mismatch Repair and Poor Prognosis in Middle Eastern Colorectal Cancers
    Abdul K. Siraj et al, 2021, Journal of Personalized Medicine CrossRef
  17. Determining Factors in the Therapeutic Success of Checkpoint Immunotherapies against PD-L1 in Breast Cancer: A Focus on Epithelial-Mesenchymal Transition Activation
    Mariana Segovia-Mendoza et al, 2021, Journal of Immunology Research CrossRef
  18. Mitosis in Cancer Cell Increases Immune Resistance via High Expression of HLA-G and PD-L1
    Matti Ullah et al, 2020, Cancers CrossRef
  19. Emerging Insights on Immunotherapy in Liver Cancer
    Ying Zhang et al, 2022, Antioxidants & Redox Signaling CrossRef
  20. Fusogenic Hybrid Extracellular Vesicles with PD-1 Membrane Proteins for the Cytosolic Delivery of Cargos
    Raga Ishikawa et al, 2022, Cancers CrossRef
  21. Like a Rolling Stone: Sting-Cgas Pathway and Cell-Free DNA as Biomarkers for Combinatorial Immunotherapy
    Guillaume Sicard et al, 2020, Pharmaceutics CrossRef
  22. Acquired radioresistance in EMT6 mouse mammary carcinoma cell line is mediated by CTLA-4 and PD-1 through JAK/STAT/PI3K pathway
    Nur Fatihah Ronny Sham et al, 2023, Scientific Reports CrossRef
  23. Sensing Soluble Immune Checkpoint Molecules and Disease-Relevant Cytokines in Cancer: A Novel Paradigm in Disease Diagnosis and Monitoring
    Nidhi Pandey et al, 2022, Frontiers in Sensors CrossRef
  24. Bifunctional Compounds as Molecular Degraders for Integrin-Facilitated Targeted Protein Degradation
    Jiwei Zheng et al, 2022, Journal of the American Chemical Society CrossRef
  25. A Novel Kinase Inhibitor AX-0085 Inhibits Interferon-γ-Mediated Induction of PD-L1 Expression and Promotes Immune Reaction to Lung Adenocarcinoma Cells
    Jusong Kim et al, 2021, Cells CrossRef
  26. Clinical applications of liquid biopsy in HPV‐negative and HPV‐positive head and neck squamous cell carcinoma: advances and challenges
    Mariana Chantre-Justino et al, 2022, Exploration of Targeted Anti-tumor Therapy CrossRef
  27. Identifying the Phenotypes of Tumor-Derived Extracellular Vesicles Using Size-Coded Affinity Microbeads
    Jiacheng Wu et al, 2022, Journal of the American Chemical Society CrossRef
  28. Activation of Host-NLRP3 Inflammasome in Myeloid Cells Dictates Response to Anti-PD-1 Therapy in Metastatic Breast Cancers
    Isak W. Tengesdal et al, 2022, Pharmaceuticals CrossRef